Thomas Jefferson University
Sidney Kimmel Medical College
Department of Dermatology & Cutaneous Biology

South, Andrew

< Back

Profile

Andrew P South, PhD

Andrew P. South, PhD

Contact Dr. South

Bluemle Life Sciences Building, Room 406
233 South Tenth Street
Philadelphia, PA 19107

(215) 955-1934

Publications

Most Recent Peer-Reviewed Publications

  1. Cells from discarded dressings differentiate chronic from acute wounds in patients with Epidermolysis Bullosa
  2. Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020
  3. Mutation signature analysis identifies increased mutation caused by tobacco smoke associated DNA adducts in larynx squamous cell carcinoma compared with oral cavity and oropharynx
  4. Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma
  5. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts
  6. Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa–associated squamous cell carcinoma
  7. Dachshund Depletion Disrupts Mammary Gland Development and Diverts the Composition of the Mammary Gland Progenitor Pool
  8. Assessment of quality and consistency of monoclonal antibodies for CB1 and CB2 in head and neck squamous cell carcinoma
  9. Retraction: Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity (Proceedings of the National Academy of Sciences of the United States of America (2017) 114 (3479–3484) DOI: 10.1073/pnas.1620982114)
  10. Precision Medicine for Heritable Skin Diseases—The Paradigm of Epidermolysis Bullosa
  11. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature
  12. Reduced Microbial Diversity Is a Feature of Recessive Dystrophic Epidermolysis Bullosa-Involved Skin and Wounds
  13. Metformin clinical trial in HPV+ and HPV-head and neck squamous cell carcinoma: Impact on cancer cell apoptosis and immune infiltrate
  14. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa
  15. The role of human papillomaviruses and polyomaviruses in BRAF-inhibitor induced cutaneous squamous cell carcinoma and benign squamoproliferative lesions
  16. First report of COL7A1 mutations in two patients with recessive dystrophic epidermolysis bullosa from Peru
  17. Seven novel COL7A1 mutations identified in patients with recessive dystrophic epidermolysis bullosa from Mexico
  18. Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis article
  19. Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
  20. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: The identification of mechanisms of differential sensitivity
  21. High concordance between clinical diagnosis of epidermolysis bullosa and immunofluorescence with a small, well-matched antibody panel
  22. Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration
  23. Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa
  24. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes
  25. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity